股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 FF301 FF301 致：香港交易及結算所有限公司 公司名稱: 金嗓子控股集團有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06896 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 5 ...

金嗓子控股集團有限公司 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED （根據開曼群島法律註冊成立的成員責任有限公司） 股份代號 : 06896 2025 中期報告 金嗓子控股集團有限公司 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED (Incorporated under the laws of the Cayman Islands with limited liability of its members) Stock code: 06896 2025 INTERIM REPORT 金嗓子控股集團有限公司 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED INTERIM REPORT 2025 中期報告 目錄 2 公司簡介 3 公司資料 5 財務摘要 6 釋義 9 管理層討論及分析 27 企業管治╱其他資料 32 中期簡明綜合損益表 33 中期簡明綜合全面收益表 34 中期簡明綜合財務狀況表 36 中期簡明綜合權益變動表 38 中期簡明綜合現金流表 40 中期簡明綜合財務資料附註 ...

公司名稱: 金嗓子控股集團有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06896 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | 本月底法定 ...

Core Viewpoint - The increasing prevalence of throat diseases due to environmental pollution, lifestyle changes, and an aging population is driving the demand for throat traditional Chinese medicine (TCM), with the market expected to reach 7.4 billion yuan in 2024, reflecting a year-on-year growth of 7.49% [1][9]. Overview - Throat diseases are primarily caused by various factors such as wind-heat invasion and internal heat, leading to symptoms like sore throat and hoarseness. Throat TCM is made from traditional Chinese medicinal ingredients and is used to treat throat-related ailments, characterized by stable efficacy and minimal side effects [1][3]. Development History - The throat medicine industry in China began relatively late, with significant advancements in chronic pharyngitis research in the 1980s leading to the development of throat medications. The market was initially fragmented, but the introduction of products like Guangxi Jinsongzi's throat lozenges in 1995 marked a turning point, establishing a competitive landscape [4][5]. Market Policy - The Chinese government has implemented various policies to support the development of the TCM industry, creating a favorable environment for throat TCM growth. These include measures to enhance TCM regulation and promote innovation [5][6]. Industry Chain - The throat TCM industry consists of an upstream segment focused on medicinal herb cultivation, a midstream segment for manufacturing, and a downstream segment involving sales through medical institutions, pharmacies, and e-commerce platforms. The primary consumer groups include individuals who use their voices frequently and patients with chronic throat conditions [6][7][8]. Current Market Situation - The throat TCM market is experiencing rapid growth, with a projected sales figure of 7.4 billion yuan in 2024. Tablets represent the largest segment at 41.65%, followed by granules and pills [1][9]. Competitive Landscape - The throat TCM market is characterized by high concentration, with the top five companies holding over 50% market share in retail pharmacies. Guangxi Jinsongzi leads with a market share of 16.95% [10][11]. Key Companies - Guangxi Jinsongzi Group is a major player in the throat TCM market, with a projected revenue of 1.185 billion yuan in 2024 and a gross profit margin of 75.46% [12]. - Guilin Sanjin Pharmaceutical Co., Ltd. is another key player, with a projected revenue of 2.194 billion yuan in 2024 and a gross profit margin of 73.41% [12]. Future Trends - The throat TCM industry is expected to focus on improving the quality of raw materials and production processes to meet rising consumer demands for high-quality products. Additionally, there is potential for international market expansion, particularly in Southeast Asia, as awareness and acceptance of TCM grow [13].

公告称，集团收益减少主要是由于2025年上半年行业形势的改变，集团产品营销策略调整，使得客户经 销商2025年上半年减少了采购所致。 金嗓子(06896)发布截至2025年6月30日止6个月的中期业绩，该集团取得收益3.19亿元，同比减少 39.14%;净利润8367.4万元，同比减少37.65%;每股基本亏损11.32分。 金嗓子 分时图 日K线 周K线 月K线 3.62 0.00 0.00% 1.66% 1.10% 0.55% 0.00% 0.55% 1.10% 1.66% 3.56 3.58 3.60 3.62 3.64 3.66 3.68 09:30 10:30 12:00/13:00 14:00 16:10 0 4万 8万 11万 ...

Core Viewpoint - The company, Jin Sang Zi (06896.HK), reported a significant decline in revenue and profit for the six months ending June 30, 2025, indicating financial challenges ahead [1] Financial Performance - The group's revenue decreased by approximately RMB 205.3 million or 39.1% to about RMB 319.2 million [1] - The earnings before interest, taxes, depreciation, and amortization (EBITDA) fell by around RMB 69.7 million or 35.6% to approximately RMB 125.9 million [1] - The profit attributable to equity holders decreased by about RMB 50.5 million or 37.6% to around RMB 83.7 million [1]

Core Viewpoint - The company reported a significant decline in revenue and net profit for the six months ending June 30, 2025, primarily due to changes in industry conditions and adjustments in marketing strategies [1] Financial Performance - The company achieved revenue of 319 million yuan, representing a year-on-year decrease of 39.14% [1] - Net profit was recorded at 83.67 million yuan, down 37.65% compared to the previous year [1] - Basic loss per share was reported at 11.32 cents [1] Market Conditions - The decline in revenue is attributed to changes in the industry landscape during the first half of 2025 [1] - Adjustments in the company's product marketing strategies led to a reduction in purchases by customers and distributors in the first half of 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED 金嗓子控股集團有限公司 （根據開曼群島法律註冊成立的成員責任有限公司） • 本集團的收益較截至2024年6月30日止六個月減少約人民幣205.3百萬元或39.1%至 約人民幣319.2百萬元。 • 本集團的毛利較截至2024年6月30日止六個月減少約人民幣145.5百萬元或37.1%至 約人民幣246.3百萬元。 • 本集團的除息稅、折舊及攤銷前盈利較截至2024年6月30日止六個月減少約人民 幣69.7百萬元或35.6%至約人民幣125.9百萬元。 • 本公司權益持有人應佔溢利較截至2024年6月30日止六個月減少約人民幣50.5百萬 元或37.6%至約人民幣83.7百萬元。 • 董事會不建議宣派任何截至2025年6月30日止六個月的中期股息。 業績 金嗓子控股集團有限公司董事會謹此宣佈本公司及其附屬公司截至20 ...

Group 1 - The company, Jin Sang Zi (06896.HK), announced that its board meeting will be held on August 28, 2025, to review and approve the interim results for the six months ending June 30, 2025 [1] - The meeting will also consider the declaration and distribution of an interim dividend, if any [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED 金嗓子控股集團有限公司（「本公司」）董事會（「董事會」）謹此宣佈，董事會會議將於2025 年8月28日（星期四）舉行，藉以（其中包括）審議及批准本公司及其附屬公司截至2025年6 月30日止六個月之中期業績及其發佈，並考慮宣派及派發中期股息（如有）。 承董事會命 金嗓子控股集團有限公司 主席 江佩珍 中國廣西 2025年8月18日 6896 董事會會議通告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.43條而作出。 於本公告日期，董事會成員包括非執行董事江佩珍女士；執行董事曾勇先生、黃建平先 生、曾克雄先生及何錦強先生；及獨立非執行董事李驊先生、朱頡榕先生、程益群先生 及覃解生先生。 ...